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Abstract
Background: Becker muscular dystrophy (BMD), a genetic disorder of X-linked recessive inheritance, typically presents
with gradually progressive muscle weakness. The condition is caused by mutations of Dystrophin gene located at
Xp21.2. Epilepsy is an infrequent manifestation of BMD, while cases of BMD with dysgnosia are extremely rare.
Case presentation: We describe a 9-year-old boy with BMD, who presented with epilepsy and dysgnosia. Serum
creatine kinase level was markedly elevated (3665 U/L). Wechsler intelligence tests showed a low intelligence quotient
(IQ = 65). Electromyogram showed slight myogenic changes and skeletal muscle biopsy revealed muscular dystrophy.
Immunohistochemical staining showed partial positivity of sarcolemma for dystrophin-N. Multiplex ligation-dependent
probe amplification revealed a duplication mutation in exons 37–44 in the Dystrophin gene.
Conclusions: The present case report helps to better understand the clinical and genetic features of BMD.
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Background
Becker muscular dystrophy (BMD), a genetic disorder of
X-linked recessive inheritance, is caused by mutations of
Dystrophin gene located at Xp21.2 [1]. The disease typ-
ically manifests as progressive muscle weakness of the
extremities and pelvic muscles. However, an estimated
7.54% BMD cases may present as epilepsy [2]. Cases of
BMD with concomitant dysgnosia are extremely rare
[3–5]. Herein, we report a case of BMD which presented
with epilepsy and dysgnosia as the initial symptom.
Case presentation
A 9-year-old boy presented to us with a 2-year-long his-
tory of episodic epileptic seizures. His growth and devel-
opment milestones were delayed compared to his peers.
He started walking at the age of 14 months and had
poor speech and mathematical ability. However, the boy
was able to walk and run normally. At the age of seven
years, he experienced his first epileptic seizure which
lasted for about 1 minute. The seizure manifested as
convulsions with sudden loss of consciousness, turning
of eyes and head tilt to the left side, and limb rigidity
(left-arm extension; right-arm flexion mimicking an
archery posture; lower-extremity flexion). There was no
history of odaxesmus or urinary incontinence. Seizure
episodes recurred at an irregular frequency. His past
medical history and family history were unremarkable.
On examination, he showed poor ability for mathem-
atical calculations (93–7 = ?), dysarthria and bilateral
enlargement of gastrocnemius muscles. Muscle strength
in the proximal muscles was 5-/5. No cranial nerve dys-
function, sensory disturbances, or ataxia was noted. All
nerve reflexes were normal.
Laboratory examination at one week after onset showed
an elevated serum creatine kinase level (3665 U/L; normal
range 25–200 U/L). Cranial magnetic resonance imaging
(MRI) was normal (Fig. 1). Wechsler intelligence tests
revealed a low intelligence quotient (IQ): total IQ 65
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(normal range, 90–109); manual IQ 63; and language IQ
72. Electromyogram showed slight myogenic changes.
Electroencephalography showed abundant interparoxys-
mal multifocal spike-slow complex waves and sharp-slow
complex waves in bilateral central-parietal areas and frontal
midline area, which is consistent with partial seizures. Skel-
etal muscle biopsy (biceps muscle) was performed after
obtaining written consent of his parents. After precooling
with isopentane, the muscle specimens were frozen in li-
quid nitrogen. Frozen sections (8 μm) were prepared and
histopathological and immunohistochemical staining per-
formed using hematoxylin-eosin (HE), modified Gomori
trichrome (MGT), NADH-tetrazolium reductase (NADH-
TR), succinate dehydrogenase (SDH), cytochrome c oxidase
(COX), acid phosphatase, periodic acid-schiff (PAS), oil red
O, dystrophin-N/C/R, sarcoglycan-α/β/γ/δ, dysferlin, and
major histocompatibility complex 1 (MHC-1).
Histopathological examination showed a few degenera-
tive, necrotic and regenerative muscle fibers and moder-
ate connective tissue hyperplasia; staining for glycogen
and lipids was negative. All enzymatic examinations
were normal. On immunohistochemical staining, sarco-
lemma showed partly positivity for dystrophin-N when
compared with normal control (Fig. 2).
Multiplex ligation-dependent probe amplification
(MLPA) showed a duplication mutation in exons 37–44
in the Dystrophin gene. Additionally, we searched the
gene bank (HGMD Pro, PubMed, 1000Genomes, and
dbSNP databases), and confirmed that this mutation was
novel. Genetic testing of his parents revealed that this
gene variant was inherited from his mother (Fig. 3).
Based on the clinical and genetic evidence, a definitive
diagnosis of BMD was made. In addition to the prescribed
[0.3 g (a.m.) and 0.6 g (p.m.)] twice daily oxcarbazepine,
the patient was administered 10 mg per day coenzyme
Q10 for approximately 2 years. Two years later his symp-
toms relieved and an EEG showed less spikes and slow
waves than it had previous shown. He had no adverse
events and his motor function remained stable.
Conclusions
The incidence of BMD is estimated to be 1.5 to 6 per
100,000 male births. Symptoms classically appear between
the ages of 8–25 years [6]. The diagnostic tests include
muscle biopsy, creatine kinase test, electromyography and
genetic testing.
The current case manifested delayed growth and de-
velopment, and physical examinations showed proximal
weakness in all extremities. Serum creatine kinase level
was elevated. Electromyogram showed slight myogenic
changes and immunohistochemical staining revealed
skeletal sarcolemma was partly positive for dystrophin-
N. DNA sequencing analysis showed a duplication muta-
tion in exons 37–44 in the Dystrophin gene. He met all
the above diagnostic criteria of BMD.
Cases of BMD presenting with epilepsy and dysgnosia
as initial symptoms are rare in the published literature.
However, the muscular involvement in this boy was
mild. Cases of BMD patients with mental disorders such
as autism and inattention are also on record [7].
Immunohistochemical staining showed that the skel-
etal sarcolemma was partly positive for dystrophin-N,
Fig. 1 Cranial magnetic resonance imaging (MRI) was normal
Fig. 2 Histopathological examination (a, hematoxylin-eosin staining, ×200) showing muscle fibers of variable sizes, few degenerative, necrotic and
regenerative muscle fibers, and moderate connective tissue hyperplasia. Immunohistochemical staining showed partial positivity of sarcolemma for
dystrophin-N (b, ×200) as compared to normal control (c, ×200)
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which suggests that the N-terminal of dystrophin protein
was significantly involved. Dystrophin protein is a rod-
shaped cytoplasmic protein located at the sarcolemmal
surface. It comprises of three domains: an N-terminal
actin-binding domain, an R-terminal domain in the mid-
dle stalk region, and a unique C-terminal domain involv-
ing a vital part of the dystrophin-associated glycoprotein
complex (DGC) that links the cytoskeleton protein to
the ion channels and the signal proteins at the surface of
the cytoplasmic membrane [8]. The mild muscular in-
volvement in this case may be associated with mild im-
pairment of DGC functions, caused by partial deficiency
of the N-terminal of dystrophin protein.
Dystrophin is encoded by one of the largest and most
complex human genes, which comprise of 79 exons.
Dystrophin gene encodes for eight isoproteins and seven
of these are expressed in the central nervous system: 3
full-length dystrophin (3 variants of Dp427), and 4
shorter non-muscle products (Dp260, Dp140, Dp116,
and Dp71) [9]. The abnormalities of Dystrophin gene
may result in structural and functional deficiency of dys-
trophin protein, which affects the contraction and relax-
ation functions of muscles.
The duplication mutation in exons 37–44 in the Dys-
trophin gene detected in this case has not been reported
previously. We speculate that this mutation affects the
structure and function of Dp140, and is likely to be a
pathogenetic variant [10]. Deficiency of Dp140 has been
shown to result in epilepsy by increasing neuronal excit-
ability (by reducing the receptors of inhibitory neuro-
transmitter GABAA and by affecting the ion channels on
the surface membranes of cells) [11]. Dp140 can also in-
duce dysgnosia by reducing the volume of gray matter
and by affecting the information processing ability [3].
Considering the main clinical manifestations of epi-
lepsy, dysgnosia, and muscular dystrophy, the differen-
tial diagnoses should include Fukuyama congenital
muscular dystrophy (FCMD), limb-girdle muscular dys-
trophy [12–14]. These conditions may present with
similar symptoms. The definitive diagnosis depends on
muscle biopsy and genetic analysis. In the future, more and
more cases will be required to more completely under-
stand and confirm genotype-phenotype relationships.
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